A Study to Evaluate the Effect of Anti-HIV Therapy on Lean Tissue (Muscle) in HIV-Positive Patients

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Keywords

ClinConnect Summary

Effective antiretroviral therapy, as measured by a decrease in HIV-1 RNA levels, may sustain or improve important components of body composition, perhaps through a decrease in the underlying pro-inflammatory activity and resting energy expenditure. Moderate weight gain has been reported to be associated with HAART. Meaningful increase in total body weight, however, may need to be comprised of augmentation of lean body mass (primarily muscle), since mortality in HIV and cancer wasting is associated with sizable decreases in lean body mass (LBM) and there is no evidence that increases in fat ...

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• Patients may be eligible for this study if they:
• • Are enrolled in an adult AIDS clinical trial.
• • Are HIV-positive.
• • Have a viral load of at least 10,000 copies/ml.
• • Are expected to live at least 6 months.
• • Are at least 18 years old.
• • Exclusion Criteria
• Patients will not be eligible for this study if they:
• • Have a history of diabetes requiring medication.
• • Have a history of heart disorders.
• • Have a fever, diarrhea, nausea, or a condition which makes it difficult to eat within the 14 days prior to study entry.
• • Have swelling due to any cause.
• • Are pregnant or breast-feeding.
• • Are receiving any therapy to increase your appetite or gain weight within 30 days prior to study entry.
• • Are receiving any therapy for a severe infection or medical illness within 14 days prior to study entry.
• • Are taking certain medications.

Trial Officials